Dejan K. Filipas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dejan K. Filipas has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Putnam Cole
Brigham and Women’s Hospital
6 shared publications Muhieddine Labban
Brigham and Women's Hospital, Division of Urological Surgery and Center of Surgery and Public Health, Boston, MA
5 shared publicationsBenjamin V. Stone
Brigham and Women's Hospital, Division of Urological Surgery and Center of Surgery and Public Health, Boston, MA
4 shared publicationsEdoardo Beatrici
Brigham and Women's Hospital, Division of Urological Surgery and Center of Surgery and Public Health, Boston, MA; Department of Urology, Humanitas Research Hospital- IRCCS, Rozzano, Milan, Italy
3 shared publications- Edoardo Beatrici
ORSI Academy Melle Belgium
3 shared publications Margit Fisch
Department of Urology University Medical Center Hamburg‐Eppendorf Hamburg Germany
3 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Wiley in BJU International
- Vol. 137 (6) , 1067-1075
Long‐term patient‐reported outcomes of open urorectal fistula repair after prostate cancer treatment
Objectives: To evaluate long‐term outcomes of open urorectal fistula (URF) repair, including URF recurrence, need for re‐intervention, and patient‐reported outcomes. Patients and Methods: This retrospective study included men undergoing open URF repair between 2014 and 2024. Data collected encompassed comorbidities, prostate cancer treatment history, prior URF interventions, and intraoperative details. Endpoints were: (i) URF recurrence‐free survival, (ii) re‐intervention‐free survival (no further disease‐related procedures), and (iii) validated patient‐reported outcome measures (PROMs). Kaplan–Meier estimators were used for survival analyses; PROMs were scored according to standard protocols. Results: A total of 29 patients underwent open URF repair. The median (interquartile range [IQR]) age was 68 (61–71) years, body mass index was 26 (23–28) kg/m 2 , and the time from prostatectomy to URF repair was 10 (4–13) months. Five patients (17%) had prior pelvic radiotherapy; 13 (45%) underwent redo repairs. Presenting symptoms included rectal urine leakage (48%), pneumaturia (24%), recurrent infections (21%), dysuria (21%), and faecaluria (10%). Transperineal repair was performed in 26 patients (90%) and transabdominal repair in three (10%). The median (IQR) operating time was 90 (80–107) min. The median follow‐up was 50 months for recurrence and 58 months for re‐intervention. The 5‐year URF recurrence‐free and any disease‐related re‐intervention‐free survival estimates were 96% and 75%, respectively. The median (IQR) six‐item lower urinary tract symptoms score from the Urethral Stricture Surgery PROM was 4 (2–8), International Consultation on Incontinence Questionnaire–Urinary Incontinence Short Form sum score was 11 (6–15), Wexner faecal incontinence score was 3 (1–9), International Consultation on Incontinence Questionnaire–Satisfaction outcome score was 21 (18–23), and Decision Regret Scale score was 0 (0–10), indicating restored voiding function, moderate urinary incontinence, mild faecal incontinence, high patient satisfaction, and negligible decisional regret. Conclusion: Open URF repair achieves durable URF closure with favourable long‐term outcomes, even in complex cases. Patient satisfaction is high, while moderate urinary incontinence persists in some, likely reflecting underlying disease. Voiding and faecal continence remain largely preserved.
- 13 March 2026
- Published by Wiley in BJU International
- Vol. 137 (6) , 1067-1075
Open AccessLong‐term patient‐reported outcomes of open urorectal fistula repair after prostate cancer treatment
Objectives: To evaluate long‐term outcomes of open urorectal fistula (URF) repair, including URF recurrence, need for re‐intervention, and patient‐reported outcomes. Patients and Methods: This retrospective study included men undergoing open URF repair between 2014 and 2024. Data collected encompassed comorbidities, prostate cancer treatment history, prior URF interventions, and intraoperative details. Endpoints were: (i) URF recurrence‐free survival, (ii) re‐intervention‐free survival (no further disease‐related procedures), and (iii) validated patient‐reported outcome measures (PROMs). Kaplan–Meier estimators were used for survival analyses; PROMs were scored according to standard protocols. Results: A total of 29 patients underwent open URF repair. The median (interquartile range [IQR]) age was 68 (61–71) years, body mass index was 26 (23–28) kg/m 2 , and the time from prostatectomy to URF repair was 10 (4–13) months. Five patients (17%) had prior pelvic radiotherapy; 13 (45%) underwent redo repairs. Presenting symptoms included rectal urine leakage (48%), pneumaturia (24%), recurrent infections (21%), dysuria (21%), and faecaluria (10%). Transperineal repair was performed in 26 patients (90%) and transabdominal repair in three (10%). The median (IQR) operating time was 90 (80–107) min. The median follow‐up was 50 months for recurrence and 58 months for re‐intervention. The 5‐year URF recurrence‐free and any disease‐related re‐intervention‐free survival estimates were 96% and 75%, respectively. The median (IQR) six‐item lower urinary tract symptoms score from the Urethral Stricture Surgery PROM was 4 (2–8), International Consultation on Incontinence Questionnaire–Urinary Incontinence Short Form sum score was 11 (6–15), Wexner faecal incontinence score was 3 (1–9), International Consultation on Incontinence Questionnaire–Satisfaction outcome score was 21 (18–23), and Decision Regret Scale score was 0 (0–10), indicating restored voiding function, moderate urinary incontinence, mild faecal incontinence, high patient satisfaction, and negligible decisional regret. Conclusion: Open URF repair achieves durable URF closure with favourable long‐term outcomes, even in complex cases. Patient satisfaction is high, while moderate urinary incontinence persists in some, likely reflecting underlying disease. Voiding and faecal continence remain largely preserved.
- Open Access
- 9 December 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (1) , 102481
Indeterminate Surgical Margins (Rx) in Renal Cell Carcinoma Surgery: Rates, Predictive Factors, and Impact on Overall Survival
- 9 December 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (1) , 102481
Open AccessIndeterminate Surgical Margins (Rx) in Renal Cell Carcinoma Surgery: Rates, Predictive Factors, and Impact on Overall Survival
- Open Access
- 19 December 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (1)
Socioeconomic determinants of cancer screening adherence among cancer survivors: analysis from the 2020 Behavioral Risk Factor Surveillance System
Background: Factors associated with cancer survivors’ preventive health behaviors are understudied. We hypothesized that socioeconomic and health-care access factors may be associated with adherence to recommended cancer screenings. Methods: We conducted a cross-sectional analysis using the 2020 Behavioral Risk Factor Surveillance System. Cancer survivors eligible for United States Preventive Services Task Force–recommended breast, cervical, prostate, and colorectal screenings were included. Multivariable logistic regression models were used to identify socioeconomic factors significantly associated with screening adherence. Results: Overall, 64 958 (weighted national estimate = 29 066 143) cancer survivors were included. Adherence rates varied across cancer types: 80.9% for breast, 88.9% for cervical, 54.1% for prostate, and 84.7% for colorectal cancer. Key predictors of low adherence included lower income (breast: adjusted odds ratio [aOR] = 0.56, 95% confidence interval [CI] = 0.43 to 0.74; cervical: aOR = 0.38, 95% CI = 0.24 to 0.59; prostate: aOR = 0.36, 95% CI = 0.24 to 0.52; colorectal: aOR = 0.74, 95% CI = 0.57 to 0.96), lack of health-care coverage for colorectal cancer (aOR = 0.51, 95% CI = 0.36 to 0.73), time since last checkup between 1 and 2 years prior for breast (aOR = 0.58, 95% CI = 0.45 to 0.75), prostate (aOR = 0.66, 95% CI = 0.47 to 0.91), and colorectal (aOR = 0.69, 95% CI = 0.56 to 0.86) cancer, and no health-care provider for breast (aOR = 0.68, 95% CI = 0.47 to 0.98), prostate (aOR = 0.45, 95% CI = 0.31 to 0.65), and colorectal (aOR = 0.51, 95% CI = 0.40 to 0.66) cancer. Conclusion: Cancer survivors’ adherence to screening is associated with factors including lack of health-care coverage, lower income, time since the last exam, and having a personal provider. Targeted interventions accounting for such factors may help mitigate these disparities.
- 19 December 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (1)
Open AccessSocioeconomic determinants of cancer screening adherence among cancer survivors: analysis from the 2020 Behavioral Risk Factor Surveillance System
Background: Factors associated with cancer survivors’ preventive health behaviors are understudied. We hypothesized that socioeconomic and health-care access factors may be associated with adherence to recommended cancer screenings. Methods: We conducted a cross-sectional analysis using the 2020 Behavioral Risk Factor Surveillance System. Cancer survivors eligible for United States Preventive Services Task Force–recommended breast, cervical, prostate, and colorectal screenings were included. Multivariable logistic regression models were used to identify socioeconomic factors significantly associated with screening adherence. Results: Overall, 64 958 (weighted national estimate = 29 066 143) cancer survivors were included. Adherence rates varied across cancer types: 80.9% for breast, 88.9% for cervical, 54.1% for prostate, and 84.7% for colorectal cancer. Key predictors of low adherence included lower income (breast: adjusted odds ratio [aOR] = 0.56, 95% confidence interval [CI] = 0.43 to 0.74; cervical: aOR = 0.38, 95% CI = 0.24 to 0.59; prostate: aOR = 0.36, 95% CI = 0.24 to 0.52; colorectal: aOR = 0.74, 95% CI = 0.57 to 0.96), lack of health-care coverage for colorectal cancer (aOR = 0.51, 95% CI = 0.36 to 0.73), time since last checkup between 1 and 2 years prior for breast (aOR = 0.58, 95% CI = 0.45 to 0.75), prostate (aOR = 0.66, 95% CI = 0.47 to 0.91), and colorectal (aOR = 0.69, 95% CI = 0.56 to 0.86) cancer, and no health-care provider for breast (aOR = 0.68, 95% CI = 0.47 to 0.98), prostate (aOR = 0.45, 95% CI = 0.31 to 0.65), and colorectal (aOR = 0.51, 95% CI = 0.40 to 0.66) cancer. Conclusion: Cancer survivors’ adherence to screening is associated with factors including lack of health-care coverage, lower income, time since the last exam, and having a personal provider. Targeted interventions accounting for such factors may help mitigate these disparities.
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (5) , 738-748
Perineal Urethrostomy for Complex Urethral Strictures: Long-Term Patient-Reported Outcomes From a Reconstructive Referral Center and a Scoping Literature Review
There is a paucity of long-term objective and patient-reported outcomes after definitive perineal urethrostomy for complex urethral strictures. Our objective is to determine comprehensive long-term success of perineal urethrostomy with our 15-year experience at a reconstructive referral center. Patients who underwent perineal urethrostomy between 2009 and 2023 were identified. A comprehensive long-term follow-up was conducted, evaluating both objective outcomes (retreatment-free survival) and subjective outcomes through the use of validated questionnaires. Additionally, to provide further context for our findings, we conducted a scoping review of all studies reporting outcomes following perineal urethrostomy. Among 76 patients, 55% had iatrogenic strictures, with 82% previously undergoing urethral interventions. At a median follow-up of 55 months, retreatment-free survival was 84%, with 16% of patients experiencing perineal urethrostomy recurrent stenosis. Patient-reported outcomes revealed a generally satisfactory voiding function (USS PROM LUTS score) and continence (ICIQ-UI SF), with median scores of 4 (range 0-24) and 0 (range 0-21), but with bimodal distributions of sexual function scores (median IIEF-EF: 3.5; median MSHQ-Ej: 21). Treatment satisfaction was very high with a median ICIQ-Satisfaction outcome score of 21 (range 0-24). The scoping review revealed varying success rates ranging from 51% to 95%, highlighting difficulties in comparison due to variable success definitions and patient case-mix. Perineal urethrostomy provides effective treatment for complex anterior urethral strictures, with high patient satisfaction, preserved continence function, and favorable voiding outcomes. It presents a viable option for older and comorbid patients, especially after thorough counseling on expected outcomes and potential risks.
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (5) , 738-748
Perineal Urethrostomy for Complex Urethral Strictures: Long-Term Patient-Reported Outcomes From a Reconstructive Referral Center and a Scoping Literature Review
There is a paucity of long-term objective and patient-reported outcomes after definitive perineal urethrostomy for complex urethral strictures. Our objective is to determine comprehensive long-term success of perineal urethrostomy with our 15-year experience at a reconstructive referral center. Patients who underwent perineal urethrostomy between 2009 and 2023 were identified. A comprehensive long-term follow-up was conducted, evaluating both objective outcomes (retreatment-free survival) and subjective outcomes through the use of validated questionnaires. Additionally, to provide further context for our findings, we conducted a scoping review of all studies reporting outcomes following perineal urethrostomy. Among 76 patients, 55% had iatrogenic strictures, with 82% previously undergoing urethral interventions. At a median follow-up of 55 months, retreatment-free survival was 84%, with 16% of patients experiencing perineal urethrostomy recurrent stenosis. Patient-reported outcomes revealed a generally satisfactory voiding function (USS PROM LUTS score) and continence (ICIQ-UI SF), with median scores of 4 (range 0-24) and 0 (range 0-21), but with bimodal distributions of sexual function scores (median IIEF-EF: 3.5; median MSHQ-Ej: 21). Treatment satisfaction was very high with a median ICIQ-Satisfaction outcome score of 21 (range 0-24). The scoping review revealed varying success rates ranging from 51% to 95%, highlighting difficulties in comparison due to variable success definitions and patient case-mix. Perineal urethrostomy provides effective treatment for complex anterior urethral strictures, with high patient satisfaction, preserved continence function, and favorable voiding outcomes. It presents a viable option for older and comorbid patients, especially after thorough counseling on expected outcomes and potential risks.
- 31 July 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102184
Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer
- 31 July 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102184
Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer
- Open Access
- 6 October 2023
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 7 (6)
The national utilization of nonoperative management for small renal masses over 10 years
Background: Management of small renal masses often involves a nonoperative approach, but there is a paucity of information about the use and associated predictors of such approaches. This study aimed to determine the trends in and predictors of use of nonoperative management of small renal masses. Methods: Using data from the National Cancer Database for localized small renal masses (N0/M0, cT1a) diagnosed between 2010 and 2020, we conducted a cross-sectional study. Nonoperative management was defined as expectant management (active surveillance or watchful waiting) or focal ablation. Adjusted odds ratios (AORs) were calculated using multivariable logistic regression models. Results: Of the 156 734 patients included, 10.5% underwent expectant management, and 13.9% underwent focal ablation. Later year of diagnosis was associated with a higher likelihood of nonoperative management. In 2020, the odds of receiving expectant management and focal ablation were 90% (AOR = 1.90, 95% confidence interval [CI] = 1.71 to 2.11) and 44% (AOR = 1.44, 95% CI = 1.31 to 1.57) higher, respectively, than in 2010. Black patients had increased odds of expectant management (AOR = 1.47, 95% CI = 1.39 to 1.55) but decreased odds of focal ablation (AOR = 0.93, 95% CI = 0.88 to 0.99). Conclusion: Over the decade, the use nonoperative management of small renal masses increased, with expectant management more frequently used than focal ablation among Black patients. Possible explanations include race-based differences in physicians' risk assessments and resource allocation. Adjusting for Black race in calculations for glomerular filtration rate could influence the differential uptake of these techniques through deflated glomerular filtration rate calculations. These findings highlight the need for research and policies to ensure equitable use of less invasive treatments in small renal masses.
- 6 October 2023
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 7 (6)
Open AccessThe national utilization of nonoperative management for small renal masses over 10 years
Background: Management of small renal masses often involves a nonoperative approach, but there is a paucity of information about the use and associated predictors of such approaches. This study aimed to determine the trends in and predictors of use of nonoperative management of small renal masses. Methods: Using data from the National Cancer Database for localized small renal masses (N0/M0, cT1a) diagnosed between 2010 and 2020, we conducted a cross-sectional study. Nonoperative management was defined as expectant management (active surveillance or watchful waiting) or focal ablation. Adjusted odds ratios (AORs) were calculated using multivariable logistic regression models. Results: Of the 156 734 patients included, 10.5% underwent expectant management, and 13.9% underwent focal ablation. Later year of diagnosis was associated with a higher likelihood of nonoperative management. In 2020, the odds of receiving expectant management and focal ablation were 90% (AOR = 1.90, 95% confidence interval [CI] = 1.71 to 2.11) and 44% (AOR = 1.44, 95% CI = 1.31 to 1.57) higher, respectively, than in 2010. Black patients had increased odds of expectant management (AOR = 1.47, 95% CI = 1.39 to 1.55) but decreased odds of focal ablation (AOR = 0.93, 95% CI = 0.88 to 0.99). Conclusion: Over the decade, the use nonoperative management of small renal masses increased, with expectant management more frequently used than focal ablation among Black patients. Possible explanations include race-based differences in physicians' risk assessments and resource allocation. Adjusting for Black race in calculations for glomerular filtration rate could influence the differential uptake of these techniques through deflated glomerular filtration rate calculations. These findings highlight the need for research and policies to ensure equitable use of less invasive treatments in small renal masses.
- 9 August 2023
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 66 (1) , 27-36
Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision Making
- 9 August 2023
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 66 (1) , 27-36
Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision Making